Abstract
Background & Aims: Eosinophilic esophagitis (EoE) can progress to fibrostenosis by unclear mechanisms. Herein, we investigated gene dysregulation in fibrostenotic EoE, its association with clinical parameters and specific pathways, and the functional consequences. Methods: Esophageal biopsies from subjects with EoE were collected across 11 Consortium of Eosinophilic Gastrointestinal Disease Researchers sites (n = 311) and 2 independent replication cohorts (n = 83). Inclusion criteria for fibrostenotic EoE were endoscopic rings, stricture, and/or a history of dilation. Endoscopic, histologic, and molecular features were assessed by the EoE Endoscopic Reference Score, EoE Histology Scoring System, EoE Diagnostic Panel, and RNA sequencing. Esophageal endothelial TSPAN12 expression and functional effects on barrier integrity and gene expression were analyzed in vitro. Results: TSPAN12 was the gene most correlated with fibrostenosis (r = −0.40, P < .001). TSPAN12 was lower in fibrostenotic EoE and correlated with EoE Endoscopic Reference Score, EoE Diagnostic Panel, and EoE Histology Scoring System (r = 0.34–0.47, P < .001). Lower TSPAN12 associated with smaller esophageal diameter (r = 0.44, P = .03), increased lamina propria fibrosis (r = −0.41, P < .001), and genes enriched in cell cycle–related pathways. Interleukin (IL)-13 reduced TSPAN12 expression in endothelial cells. Conversely, anti–IL-13 therapy increased TSPAN12 expression. TSPAN12 gene silencing increased endothelial cell permeability and dysregulated genes associated with extracellular matrix pathways. Endothelial cell–fibroblast crosstalk induced extracellular matrix changes relevant to esophageal remodeling. Conclusions: Patients with fibrostenotic EoE express decreased levels of endothelial TSPAN12. We propose that IL-13 decreases TSPAN12, likely contributing to the chronicity of EoE by promoting tissue remodeling through fibroblast-endothelial cell crosstalk.
Original language | English |
---|---|
Pages (from-to) | 439-453 |
Number of pages | 15 |
Journal | Gastroenterology |
Volume | 162 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2022 |
Keywords
- Endothelium
- Eosinophil
- Eosinophilic Esophagitis
- Fibrosis
- Transcriptome
Access to Document
Fingerprint
Dive into the research topics of 'Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell–Fibroblast Crosstalk'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Gastroenterology, Vol. 162, No. 2, 02.2022, p. 439-453.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell–Fibroblast Crosstalk
AU - Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators Group
AU - Shoda, Tetsuo
AU - Wen, Ting
AU - Caldwell, Julie M.
AU - Ben-Baruch Morgenstern, Netali
AU - Osswald, Garrett A.
AU - Rochman, Mark
AU - Mack, Lydia E.
AU - Felton, Jennifer M.
AU - Abonia, J. Pablo
AU - Arva, Nicoleta C.
AU - Atkins, Dan
AU - Bonis, Peter A.
AU - Capocelli, Kelley E.
AU - Collins, Margaret H.
AU - Dellon, Evan S.
AU - Falk, Gary W.
AU - Gonsalves, Nirmala
AU - Gupta, Sandeep K.
AU - Hirano, Ikuo
AU - Leung, John
AU - Menard-Katcher, Paul A.
AU - Mukkada, Vincent A.
AU - Putnam, Philip E.
AU - Rudman Spergel, Amanda K.
AU - Spergel, Jonathan M.
AU - Wechsler, Joshua B.
AU - Yang, Guang Yu
AU - Aceves, Seema S.
AU - Furuta, Glenn T.
AU - Rothenberg, Marc E.
AU - Aceves, Seema
AU - Almonte, Samuel
AU - Andrews, Rachel
AU - Arrington, Ashley
AU - Arva, Nicoleta
AU - Atkins, Fred
AU - Bailey, Dominique
AU - Berry, Alexis
AU - Besl, Bridget
AU - Bolton, Scott
AU - Bonis, Peter
AU - Book, Wendy
AU - Bray, Kimberly
AU - Brown, Teresa
AU - Burger, Cassandra
AU - Burke, Deirdre
AU - Cahoon, Jonathon
AU - Capocelli, Kelley
AU - Chehade, Mirna
AU - Collins, Margaret
N1 - Funding Information: Funding This study was supported by NIH grant K99/R00 AI158660 (to T.S.) and CEGIR (U54 AI117804), which is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), and is co-funded by the National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and NCATS. CEGIR is also supported by patient advocacy groups, including the American Partnership for Eosinophilic Disorders, Campaign Urging Research for Eosinophilic Disease, and Eosinophilic Family Coalition. As a member of the RDCRN, CEGIR is also supported by its Data Management and Coordinating Center (U2CTR002818). Funding Information: Conflicts of interest These authors disclose the following: Marc E. Rothenberg is a consultant for Pulm One, Spoon Guru, Allakos, ClostraBio, Serpin Pharm, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis; has an equity interest in the first 5, as well as royalties from reslizumab (Teva Pharmaceuticals) and Up-To-Date; and is an inventor of patents, owned by Cincinnati Children’s. Gary W. Falk has received research support from Lucid, Allakos, Regeneron, Takeda/Shire, and Adare, and is a consultant for Adare, Allakos, Lucid and Takeda/Shire. Ikuo Hirano is a consultant for Adare, Allakos, Arena, AstraZeneca, Boston Scientific, Eli Lilly, EsoCap, Gossamer Bio, Parexel, Receptos/Celegene/BMS, Regeneron, and Shire/Takeda, and has received research funding from Adare, Allakos, Meritage, Receptos/Celgene/BMS, Regeneron, and Shire/Takeda. Margaret H. Collins is a consultant for Allakos, Arena, Astra Zeneca, Calypso, GSK, Meritage/Shire/Takeda, Robarts/Alimentiv, Regeneron, Receptos/Celgene/BMS, and Esocap, and has received research funding from Meritage/Shire/Takeda, Regeneron, Receptos, and Astra Zeneca. Sandeep K. Gupta is a consultant for Abbott, Adare, Allakos, Gossamer Bio, MedScape, QOL, Receptos/Celgene, UpToDate, and Viaskin, and receives research support from Shire. Vincent A. Mukkada is a consultant for Shire and has received research funding from Shire. Nirmala Gonsalves is a consultant for Allakos. Evan S. Dellon is a consultant for Abbott, Adare, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Biorasi, Calypso, Eli Lilly, EsoCap, Gossamer Bio, GlaxoSmithKline, Parexel, Receptos/Celegene/BMS, Regeneron, Robarts, Salix, and Shire/Takeda; has received research funding from Adare, Allakos, GlaxoSmithKline, Meritage, Miraca, Nutricia, Receptos/Celgene/BMS, Regeneron, and Shire/Takeda; and has received educational grants from Allakos, Banner, and Holoclara. Seema S. Aceves is a consultant for Regeneron, AImmune Therapeutics, DBV, and AstraZeneca, and is an inventor of oral viscous budesonide, patented by UCSD and licensed by Shire/Takeda. Jonathan M. Spergel is a consultant for Regeneron and DBV Technology, and his research is supported by the National Institutes of Health, Everbody Eats (EATS) foundation, AImmune Therapeutics, Food Allergy Research & Education (FARE), and DBV Technology. Glenn T. Furuta is a consultant for Shire and a co-founder of EnteroTrack. Joshua B. Wechsler is a consultant for Allakos and Regeneron. John Leung is a consultant for Adare, Eli Lilly, AbbVie, Genzyme, and Shire/Takeda, and has received research funding from Adare, Allakos, Celgene, Regeneron, AstraZeneca, and Shire/Takeda. Amanda K. Rudman Spergel’s co-authorship of this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, or any other agency of the U.S. government. The remaining authors disclose no conflicts. Funding Information: The authors thank all patients who participated in the study. The authors are also grateful to their colleagues and clinical support staff for procuring biopsies and clinical data. Shawna Hottinger provided editorial assistance as a medical writer funded by Cincinnati Children's Hospital Medical Center. Order of Authors (with Contributor Roles):, Tetsuo Shoda, MD, PhD (Data curation: Equal; Formal analysis: Lead; Investigation:, Lead; Methodology: Lead; Writing ? original draft: Lead), Ting Wen, MD, PhD (Formal analysis: Supporting; Investigation: Supporting;, Methodology: Supporting; Supervision: Supporting), Julie M. Caldwell, PhD (Project administration: Supporting; Resources: Supporting), Netali Ben-Baruch Morgenstern, PhD (Formal analysis: Supporting; Software: Supporting), Garrett A. Osswald, BS (Resources: Supporting), Mark Rochman, PhD (Software: Supporting), Lydia E. Mack, MS (Resources: Supporting), Jennifer M. Felton, PhD (Software: Supporting), J. Pablo Abonia, MD (Project administration: Supporting), Nicoleta C. Arva, MD, PhD (Project administration: Supporting), Dan Atkins, MD (Project administration: Supporting), Peter A. Bonis, MD (Project administration: Supporting; Writing ? review & editing: Supporting), Kelley E. Capocelli, MD (Project administration: Supporting), Margaret H. Collins, MD (Project administration: Supporting; Writing ? review & editing: Supporting), Evan S. Dellon, MD, MPH (Project administration: Supporting; Writing ? review & editing: Supporting), Gary W. Falk, MD, MS (Project administration: Supporting; Writing ? review & editing: Supporting), Nirmala Gonsalves, MD (Project administration: Supporting), Sandeep K. Gupta, MD (Project administration: Supporting; Writing ? review & editing: Supporting), Ikuo Hirano, MD (Project administration: Supporting), John Leung, MD (Project administration: Supporting), Paul A. Menard-Katcher, MD (Project administration: Supporting), Vincent A. Mukkada, MD (Project administration: Supporting), Philip E. Putnam, MD (Project administration: Supporting), Amanda K. Rudman Spergel, MD (Project administration: Supporting), Jonathan M. Spergel, MD, PhD (Project administration: Supporting), Joshua B. Wechsler, MD, MS (Project administration: Supporting), Guang-Yu Yang, MD (Project administration: Supporting), Seema S. Aceves, MD, PhD (Project administration: Supporting; Writing ? review & editing: Supporting), Glenn T. Furuta, MD (Project administration: Supporting; Writing ? review & editing: Supporting), Marc E. Rothenberg, MD, PhD (Conceptualization: Equal; Funding acquisition: Lead;, Project administration: Lead; Supervision: Lead; Writing ? review & editing: Lead) Conflicts of interest These authors disclose the following: Marc E. Rothenberg is a consultant for Pulm One, Spoon Guru, Allakos, ClostraBio, Serpin Pharm, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis; has an equity interest in the first 5, as well as royalties from reslizumab (Teva Pharmaceuticals) and Up-To-Date; and is an inventor of patents, owned by Cincinnati Children's. Gary W. Falk has received research support from Lucid, Allakos, Regeneron, Takeda/Shire, and Adare, and is a consultant for Adare, Allakos, Lucid and Takeda/Shire. Ikuo Hirano is a consultant for Adare, Allakos, Arena, AstraZeneca, Boston Scientific, Eli Lilly, EsoCap, Gossamer Bio, Parexel, Receptos/Celegene/BMS, Regeneron, and Shire/Takeda, and has received research funding from Adare, Allakos, Meritage, Receptos/Celgene/BMS, Regeneron, and Shire/Takeda. Margaret H. Collins is a consultant for Allakos, Arena, Astra Zeneca, Calypso, GSK, Meritage/Shire/Takeda, Robarts/Alimentiv, Regeneron, Receptos/Celgene/BMS, and Esocap, and has received research funding from Meritage/Shire/Takeda, Regeneron, Receptos, and Astra Zeneca. Sandeep K. Gupta is a consultant for Abbott, Adare, Allakos, Gossamer Bio, MedScape, QOL, Receptos/Celgene, UpToDate, and Viaskin, and receives research support from Shire. Vincent A. Mukkada is a consultant for Shire and has received research funding from Shire. Nirmala Gonsalves is a consultant for Allakos. Evan S. Dellon is a consultant for Abbott, Adare, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Biorasi, Calypso, Eli Lilly, EsoCap, Gossamer Bio, GlaxoSmithKline, Parexel, Receptos/Celegene/BMS, Regeneron, Robarts, Salix, and Shire/Takeda; has received research funding from Adare, Allakos, GlaxoSmithKline, Meritage, Miraca, Nutricia, Receptos/Celgene/BMS, Regeneron, and Shire/Takeda; and has received educational grants from Allakos, Banner, and Holoclara. Seema S. Aceves is a consultant for Regeneron, AImmune Therapeutics, DBV, and AstraZeneca, and is an inventor of oral viscous budesonide, patented by UCSD and licensed by Shire/Takeda. Jonathan M. Spergel is a consultant for Regeneron and DBV Technology, and his research is supported by the National Institutes of Health, Everbody Eats (EATS) foundation, AImmune Therapeutics, Food Allergy Research & Education (FARE), and DBV Technology. Glenn T. Furuta is a consultant for Shire and a co-founder of EnteroTrack. Joshua B. Wechsler is a consultant for Allakos and Regeneron. John Leung is a consultant for Adare, Eli Lilly, AbbVie, Genzyme, and Shire/Takeda, and has received research funding from Adare, Allakos, Celgene, Regeneron, AstraZeneca, and Shire/Takeda. Amanda K. Rudman Spergel's co-authorship of this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, or any other agency of the U.S. government. The remaining authors disclose no conflicts. Funding This study was supported by NIH grant K99/R00 AI158660 (to T.S.) and CEGIR (U54 AI117804), which is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), and is co-funded by the National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and NCATS. CEGIR is also supported by patient advocacy groups, including the American Partnership for Eosinophilic Disorders, Campaign Urging Research for Eosinophilic Disease, and Eosinophilic Family Coalition. As a member of the RDCRN, CEGIR is also supported by its Data Management and Coordinating Center (U2CTR002818). Publisher Copyright: © 2022 AGA Institute
PY - 2022/2
Y1 - 2022/2
N2 - Background & Aims: Eosinophilic esophagitis (EoE) can progress to fibrostenosis by unclear mechanisms. Herein, we investigated gene dysregulation in fibrostenotic EoE, its association with clinical parameters and specific pathways, and the functional consequences. Methods: Esophageal biopsies from subjects with EoE were collected across 11 Consortium of Eosinophilic Gastrointestinal Disease Researchers sites (n = 311) and 2 independent replication cohorts (n = 83). Inclusion criteria for fibrostenotic EoE were endoscopic rings, stricture, and/or a history of dilation. Endoscopic, histologic, and molecular features were assessed by the EoE Endoscopic Reference Score, EoE Histology Scoring System, EoE Diagnostic Panel, and RNA sequencing. Esophageal endothelial TSPAN12 expression and functional effects on barrier integrity and gene expression were analyzed in vitro. Results: TSPAN12 was the gene most correlated with fibrostenosis (r = −0.40, P < .001). TSPAN12 was lower in fibrostenotic EoE and correlated with EoE Endoscopic Reference Score, EoE Diagnostic Panel, and EoE Histology Scoring System (r = 0.34–0.47, P < .001). Lower TSPAN12 associated with smaller esophageal diameter (r = 0.44, P = .03), increased lamina propria fibrosis (r = −0.41, P < .001), and genes enriched in cell cycle–related pathways. Interleukin (IL)-13 reduced TSPAN12 expression in endothelial cells. Conversely, anti–IL-13 therapy increased TSPAN12 expression. TSPAN12 gene silencing increased endothelial cell permeability and dysregulated genes associated with extracellular matrix pathways. Endothelial cell–fibroblast crosstalk induced extracellular matrix changes relevant to esophageal remodeling. Conclusions: Patients with fibrostenotic EoE express decreased levels of endothelial TSPAN12. We propose that IL-13 decreases TSPAN12, likely contributing to the chronicity of EoE by promoting tissue remodeling through fibroblast-endothelial cell crosstalk.
AB - Background & Aims: Eosinophilic esophagitis (EoE) can progress to fibrostenosis by unclear mechanisms. Herein, we investigated gene dysregulation in fibrostenotic EoE, its association with clinical parameters and specific pathways, and the functional consequences. Methods: Esophageal biopsies from subjects with EoE were collected across 11 Consortium of Eosinophilic Gastrointestinal Disease Researchers sites (n = 311) and 2 independent replication cohorts (n = 83). Inclusion criteria for fibrostenotic EoE were endoscopic rings, stricture, and/or a history of dilation. Endoscopic, histologic, and molecular features were assessed by the EoE Endoscopic Reference Score, EoE Histology Scoring System, EoE Diagnostic Panel, and RNA sequencing. Esophageal endothelial TSPAN12 expression and functional effects on barrier integrity and gene expression were analyzed in vitro. Results: TSPAN12 was the gene most correlated with fibrostenosis (r = −0.40, P < .001). TSPAN12 was lower in fibrostenotic EoE and correlated with EoE Endoscopic Reference Score, EoE Diagnostic Panel, and EoE Histology Scoring System (r = 0.34–0.47, P < .001). Lower TSPAN12 associated with smaller esophageal diameter (r = 0.44, P = .03), increased lamina propria fibrosis (r = −0.41, P < .001), and genes enriched in cell cycle–related pathways. Interleukin (IL)-13 reduced TSPAN12 expression in endothelial cells. Conversely, anti–IL-13 therapy increased TSPAN12 expression. TSPAN12 gene silencing increased endothelial cell permeability and dysregulated genes associated with extracellular matrix pathways. Endothelial cell–fibroblast crosstalk induced extracellular matrix changes relevant to esophageal remodeling. Conclusions: Patients with fibrostenotic EoE express decreased levels of endothelial TSPAN12. We propose that IL-13 decreases TSPAN12, likely contributing to the chronicity of EoE by promoting tissue remodeling through fibroblast-endothelial cell crosstalk.
KW - Endothelium
KW - Eosinophil
KW - Eosinophilic Esophagitis
KW - Fibrosis
KW - Transcriptome
UR - http://www.scopus.com/inward/record.url?scp=85121747513&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2021.10.016
DO - 10.1053/j.gastro.2021.10.016
M3 - Article
C2 - 34687736
AN - SCOPUS:85121747513
SN - 0016-5085
VL - 162
SP - 439
EP - 453
JO - Gastroenterology
JF - Gastroenterology
IS - 2
ER -